SLP7111228 

SLP7111228 is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 can be used in research related to neuroinflammatory diseases and pulmonary hypertension^[1][2].

SLP7111228 (1 µM; 30 min pre-incubation, 4 h LPS incubation) significantly reduces LPS-induced IL-1β mRNA expression in BV2 mouse microglia cells, with a non-significant reduction in TNFα mRNA expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SLP7111228 (10 mg/kg; i.p.; daily; 3 weeks) reduces plasma S1P levels, reverses occlusive pulmonary arteriopathy, and improves cardiac function in late-stage Su/Hx/Nx PAH rats, without reducing right ventricular systolic pressure or hypertrophy^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

383.53

C₂₂H₃₃N₅O

1449765-82-5

CCCCCCCCC(C=C1)=CC=C1C2=NOC(C[C@H]3N(CCC3)C(N)=N)=N2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Standoli S, et al. Sphingosine Kinases at the Intersection of Pro-Inflammatory LPS and Anti-Inflammatory Endocannabinoid Signaling in BV2 Mouse Microglia Cells. Int J Mol Sci. 2023 May 9;24(10):8508.  [Content Brief]

  [2]. Gairhe S, et al. Sphingosine-1-phosphate is involved in the occlusive arteriopathy of pulmonary arterial hypertension. Pulm Circ. 2016;6(3):369-380.